Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med. 2020;173(1):57-58.

Article  PubMed  Google Scholar 

Mehrotra A, Chernew M, Linetsky D, Hatch H, Cutler D. The impact of the COVID-19 pandemic on outpatient visits: A rebound emerges. The Commonwealth Fund; 2020: https://www.commonwealthfund.org/publications/2020/apr/impact-covid-19-outpatient-visits. Accessed 16 December 2020.

Epic Health Research Network. Expansion of Telehealth during COVID-19 Pandemic. https://ehrnprd.blob.core.windows.net/wordpress/pdfs/Expansions-in-Telehealth-COVID-19. Published 2020. Accessed 26 October 2020.

Martin K, Kurowski D, Given P. The Impact of COVID-19 on the Use of Preventive Health Care. Health Care Cost Institute. https://healthcostinstitute.org/hcci-research/the-impact-of-covid-19-on-the-use-of-preventive-health-care. Published 2020. Accessed 26 October 2020.

Czeisler ME, Lane RI, Petrosky E, et al. Mental health, substance use, and suicidal ideation during the COVID-19 Pandemic - United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1049-1057.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130-140.

Article  PubMed  Google Scholar 

Panchal N, Kamal R, Orgera K, et al. The Implications of COVID-19 for Mental Health and Substance Use. Kaiser Family Foundation. https://www.kff.org/coronavirus-covid-19/issue-brief/the-implications-of-covid-19-for-mental-health-and-substance-use/. Published 2020. Accessed 1 September 2021.

Friedman J, Beletsky L, Schriger DL. Overdose-related cardiac arrests observed by emergency medical services during the US COVID-19 Epidemic. JAMA Psychiatry. 2021;78(5):562-564.

Article  PubMed  Google Scholar 

Friedman J, Mann NC, Hansen H, et al. Racial/ethnic, social, and geographic trends in overdose-associated cardiac arrests observed by US emergency medical services during the COVID-19 pandemic. JAMA Psychiatry. 2021;78(8):886-895.

Article  PubMed  PubMed Central  Google Scholar 

Khatri UG, Pizzicato LN, Viner K, et al. Racial/ethnic disparities in unintentional fatal and nonfatal emergency medical services-attended opioid overdoses during the COVID-19 pandemic in Philadelphia. JAMA Netw Open. 2021;4(1):e2034878.

Article  PubMed  PubMed Central  Google Scholar 

Soares WE 3rd, Melnick ER, Nath B, et al. Emergency department visits for nonfatal opioid overdose during the COVID-19 pandemic across six US health care systems. Ann Emerg Med. 2022;79(2):158-167.

Article  PubMed  Google Scholar 

Spencer M, Garnett M, Minino A. Drug overdose deaths in the United States, 2002–2022. NCHS Data Brief. 2024. https://www.cdc.gov/nchs/products/databriefs/db491.htm. Published March. Accessed 30 September 2024.

Goldman ML, Druss BG, Horvitz-Lennon M, et al. Mental health policy in the era of COVID-19. Psychiatr Serv. 2020;71(11):1158-1162.

Article  PubMed  Google Scholar 

Davis CS, Carr DH, Glenn MJ, Samuels EA. Legal authority for emergency medical services to increase access to buprenorphine treatment for opioid use disorder. Ann Emerg Med. 2021;78(1):102-108.

Article  PubMed  PubMed Central  Google Scholar 

Andraka-Christou B, Bouskill K, Haffajee RL, et al. Common themes in early state policy responses to substance use disorder treatment during COVID-19. Am J Drug Alcohol Abuse. 2021;47(4):486-496.

Article  PubMed  PubMed Central  Google Scholar 

National Conference of State Legislatures. Behavioral Health and COVID-19: POLICY SNAPSHOT. https://www.ncsl.org/Portals/1/Documents/Health/COVID-Behavioral-Health_snapshot_35149.pdf. Published 2020. Accessed 9 August 2021.

Pessar SC, Boustead A, Ge Y, Smart R, Pacula RL. Assessment of State and Federal Health policies for opioid use disorder treatment during the COVID-19 Pandemic and Beyond. JAMA Health Forum. 2021;2(11):e213833.

Article  PubMed  PubMed Central  Google Scholar 

State of the Response: State Actions to Address the Pandemic Report Methodology. National Safety Council: https://www.nsc.org/getmedia/10cf1e25-92af-4caa-b5c1-b22114468cf1/state-response-report-methodology.pdf. Accessed 17 October 2022.

Perumalswami PV, Kilpatrick S, Frost MC, et al. The impact of COVID-19 on trends in alcohol use disorder treatment in Veterans Health Administration. Addiction. 2023;118(6):1062-1071.

Article  PubMed  Google Scholar 

Nguyen TD, Gupta S, Ziedan E, et al. Assessment of filled buprenorphine prescriptions for opioid use disorder during the Coronavirus disease 2019 pandemic. JAMA Intern Med. 2020.

Chalasani R, Shinabery JM, Goetz CT, et al. Buprenorphine dispensing in Pennsylvania during the COVID-19 pandemic, January to October 2020. J Gen Intern Med. 2021;36(12):3915-3917.

Article  PubMed  PubMed Central  Google Scholar 

Currie JM, Schnell MK, Schwandt H, Zhang J. Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 Pandemic. JAMA Netw Open. 2021;4(4):e216147.

Article  PubMed  PubMed Central  Google Scholar 

Cantor J, Dick AW, Haffajee R, et al. Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic. J Subst Abuse Treat. 2021;129:108384.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jones CM, Guy GP Jr., Board A. Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020. Drug Alcohol Depend. 2021;219:108486.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huskamp HA, Busch AB, Uscher-Pines L, Barnett ML, Riedel L, Mehrotra A. Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic. JAMA. 2020;324(23):2440-2442.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cance JD, Doyle E. Changes in outpatient buprenorphine dispensing during the COVID-19 pandemic. JAMA. 2020;324(23):2442-2444.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stein BD, Landis RK, Sheng F, et al. Buprenorphine treatment episodes during the first year of COVID: a retrospective examination of treatment initiation and retention. J Gen Intern Med. 2023;38(3):733-737.

Article  PubMed  Google Scholar 

Langabeer JR, 2nd, Yatsco A, Champagne-Langabeer T. Telehealth sustains patient engagement in OUD treatment during COVID-19. J Subst Abuse Treat. 2021;122:108215.

Article  CAS  PubMed  Google Scholar 

Samuels EA, Khatri UG, Snyder H, Wightman RS, Tofighi B, Krawczyk N. Buprenorphine telehealth treatment initiation and follow-up during COVID-19. J Gen Intern Med. 2022;37(5):1331-1333.

Article  PubMed  PubMed Central  Google Scholar 

Jones CM, Diallo MM, Vythilingam M, Schier JG, Eisenstat M, Compton WM. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic. Drug Alcohol Depend. 2021;225:108783.

Riedel L, Uscher-Pines L, Mehrotra A, et al. Use of telemedicine for opioid use disorder treatment - Perceptions and experiences of opioid use disorder clinicians. Drug Alcohol Depend. 2021;228:108999.

Article  PubMed  PubMed Central  Google Scholar 

Uscher-Pines L, Sousa J, Raja P, Mehrotra A, Barnett M, Huskamp HA. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine. J Subst Abuse Treat. 2020;118:108124.

Article  PubMed  PubMed Central  Google Scholar 

Huskamp HA, Riedel L, Uscher-Pines L, et al. Initiating opioid use disorder medication via telemedicine during COVID-19: Implications for proposed reforms to the Ryan Haight Act. J Gen Intern Med. 2022;37(1):162-167.

Article  PubMed  Google Scholar 

Agniel D, Cantor J, Golan OK, et al. How are state telehealth policies associated with services offered by substance use disorder treatment facilities? Evidence from 2019 to 2022. Drug Alcohol Depend. 2023;252:110959.

Article  PubMed  PubMed Central  Google Scholar 

Wunsch C, Wightman R, Pratty C, et al. Thirty-day treatment continuation after audio-only buprenorphine telehealth initiation. J Addict Med. 2023;17(2):206-209.

Article  PubMed  Google Scholar 

Frost MC, Zhang L, Kim HM, Lin LA. Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. JAMA Netw Open. 2022;5(10):e2236298.

Article  PubMed  PubMed Central  Google Scholar 

Vakkalanka JP, Lund BC, Ward MM, et al. Telehealth utilization is associated with lower risk of discontinuation of buprenorphine: a retrospective cohort study of US Veterans. J Gen Intern Med. 2022;37(7):1610-1618.

Article